Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LMP2-loaded dendritic cell vaccine + DUK-CPG-001
- Development stage
- Unknown
- Lead developer
- Duke University
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
LMP2-loaded dendritic cell vaccine + DUK-CPG-001 is an investigational combination immunotherapy developed at Duke University for the treatment of Epstein-Barr Virus (EBV)-positive Hodgkin and non-Hodgkin lymphomas. The regimen consists of an autologous dendritic cell vaccine pulsed with the EBV Latent Membrane Protein 2 (LMP2) antigen, which is designed to stimulate a specific cytotoxic T-lymphocyte response against tumor cells expressing EBV antigens. This is co-administered with DUK-CPG-001, a synthetic oligonucleotide that acts as a Toll-like receptor 9 (TLR9) agonist. DUK-CPG-001 functions as an adjuvant, enhancing the maturation and activity of the dendritic cells and promoting a robust Th1-type immune response. The therapy is typically evaluated in the setting of autologous stem cell transplant to consolidate remission and prevent relapse.
- Other names
- LMP2A-loaded conventional DC vaccineLMP-2A-loaded conventional DC vaccineLMP 2A-loaded conventional DC vaccineEBV-derived DC vaccineEBV-derived LMP2-loaded DC vaccine
02
Targets
TLR9 (Toll-like receptor 9)Epstein-Barr virus latent membrane protein 2-specific T-cell receptor
Beyond the preview
Go deeper on LMP2-loaded dendritic cell vaccine + DUK-CPG-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LMP2-loaded dendritic cell vaccine + DUK-CPG-001.